What is PCOS and why does insulin resistance sit at the center of it?
Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women, affecting an estimated 5 to 10 percent of women of reproductive age in the United States, with some research placing the figure as high as one in five. The condition involves a cluster of symptoms including irregular menstrual cycles, elevated androgen levels (male hormones such as testosterone), and small fluid-filled follicles on one or both ovaries. No single cause explains every case, but insulin resistance sits at the center of the problem for the majority of patients.
Between 50 and 80 percent of women with PCOS have some degree of insulin resistance, meaning their cells do not respond normally to insulin. The body compensates by producing more insulin. High circulating insulin then stimulates the ovaries to produce excess androgens, which disrupt ovulation, cause irregular periods, and contribute to symptoms like acne and unwanted hair growth. At the same time, insulin resistance promotes fat storage around the abdomen, which worsens the hormonal environment further. Studies estimate that up to 40 percent of women with PCOS have developed prediabetes or type 2 diabetes by age 40.
This overlap between insulin resistance and PCOS is exactly why medications that improve insulin sensitivity have long been used in PCOS management. Metformin, approved for type 2 diabetes, has been prescribed off-label for PCOS for decades. The newer class of GLP-1 receptor agonists works through a different but overlapping mechanism, and is drawing significant research interest for the same reason.
What GLP-1 receptor agonists are actually approved for
GLP-1 receptor agonists are a class of injectable (and in some cases oral) medications that mimic glucagon-like peptide-1, a hormone released by the gut after eating. They stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. FDA-approved GLP-1 receptor agonists include semaglutide, approved as Ozempic for type 2 diabetes and as Wegovy for chronic weight management, and tirzepatide, approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.
None of these medications carry an FDA-approved indication for PCOS. Any GLP-1 receptor agonist prescribed specifically for PCOS is being used off-label, meaning the prescribing clinician is applying published evidence and clinical judgment outside a formally approved indication. Off-label prescribing is legal and common in medicine, and it can reflect strong emerging evidence even before a regulatory approval follows.
Compounded semaglutide and compounded tirzepatide, available through some telehealth platforms, are not FDA-approved drugs. They are prepared by state-licensed compounding pharmacies or FDA-registered 503B outsourcing facilities and dispensed for individual patients based on a valid prescription. Compounded formulations have not been evaluated in the same clinical trials as the FDA-approved branded medications, and the FDA has not reviewed them for safety, efficacy, or quality. All clinical trial data discussed in this article refers to studies of FDA-approved GLP-1 receptor agonists, not to compounded products.
How GLP-1 receptor agonists reduce the insulin resistance driving PCOS
GLP-1 receptor agonists lower insulin resistance through several pathways that are particularly relevant to PCOS. They stimulate insulin secretion in a glucose-dependent way, meaning they help the pancreas respond to actual blood glucose elevations rather than chronically overproducing insulin. They also reduce visceral adipose tissue, the fat stored around the abdomen that is a primary driver of peripheral insulin resistance. A third pathway involves suppressing pro-inflammatory signals including TNF-alpha and interleukin-6, cytokines that directly interfere with insulin signaling at the cellular level.
As insulin resistance decreases, the ovaries receive less stimulation to overproduce androgens. Simultaneously, weight loss increases the liver's production of sex hormone-binding globulin (SHBG), a protein that binds to free testosterone and reduces its biological activity. A study of liraglutide in obese women with PCOS found that 26 weeks of treatment increased SHBG by 19 percent and decreased free testosterone by 19 percent. Those hormonal shifts can translate into reduced acne, less unwanted hair growth, and more regular menstrual cycles. This study was conducted with FDA-approved liraglutide. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent trials; these results cannot be assumed to apply to compounded formulations.
GLP-1 receptors have also been identified in the hypothalamus and pituitary gland, which regulate the hormonal signals that control the menstrual cycle. This suggests these medications may have some direct effects on reproductive hormone signaling beyond what is explained by weight loss alone, though the extent of those direct effects is still being studied.
What clinical trials show about GLP-1s, weight, and metabolism in PCOS
A growing body of randomized controlled trial data supports GLP-1 receptor agonists for metabolic improvements in PCOS. A systematic review and meta-analysis published in the European Journal of Endocrinology analyzed 11 randomized controlled trials in women with PCOS and found that GLP-1 receptor agonists reduced BMI by a mean of 1.38 kg/m² compared to controls overall, and by 2.18 kg/m² compared to placebo specifically. Narrative findings also favored GLP-1 treatment for menstrual regularity, though the authors rated the certainty of evidence as low to very low, reflecting the relatively small sizes and short durations of available trials.
A more recent prospective randomized trial published in Reproductive Biology and Endocrinology enrolled 100 overweight or obese women with PCOS and assigned them to either metformin alone or a combination of metformin and semaglutide (at doses up to 1 mg weekly) for 16 weeks. The combination group lost an average of 6.09 kg versus 2.25 kg in the metformin-only group. Both groups showed improvements in insulin resistance measured by HOMA-IR, with no significant difference between them on that metric, though the combination group showed greater reductions in inflammatory markers.
These trials examined FDA-approved GLP-1 receptor agonists including liraglutide, exenatide, and semaglutide in their approved formulations. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent controlled trials. The results from research on approved drugs cannot be assumed to apply to compounded formulations.
Do GLP-1s improve menstrual cycles and androgen levels in PCOS?
Menstrual cycle restoration is one of the most clinically meaningful outcomes observed in GLP-1 trials involving women with PCOS. In the semaglutide-plus-metformin randomized controlled trial described above, 72.5 percent of women in the combination group experienced menstrual cycle recovery at 16 weeks, compared to 42.3 percent in the metformin-only group, a statistically significant difference.
A scoping review of GLP-1 receptor agonist use in women with PCOS examined eight published studies and found that both liraglutide and exenatide treatment correlated with improved menstrual regularity and increased spontaneous pregnancy rates. Hormonal analysis across studies showed decreased testosterone levels and increased SHBG following GLP-1 therapy, suggesting at least partial restoration of hormonal balance. These studies involved FDA-approved liraglutide and exenatide in their approved formulations. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent PCOS-specific trials.
Weight loss appears to be the primary driver of these reproductive improvements rather than any direct drug action on the ovary. Evidence from PCOS weight loss research supports that even modest reductions in body weight can matter meaningfully. A post-hoc analysis of the BAMBINI randomized controlled trial found that each one percent reduction in body weight was associated with a 5.6 percent increase in the odds of ovulatory recovery in women with PCOS and obesity. At 52 weeks, more than half of women who lost weight had restored ovulatory function. No upper threshold of weight loss that reduced ovulatory recovery was identified, meaning more substantial weight loss did not appear to be harmful to reproductive outcomes in this study.
The fertility paradox: why improved ovulation requires a clear plan
Improved menstrual regularity and restored ovulatory function are generally positive outcomes for women with PCOS who want to conceive. However, this creates an important consideration for women who are not trying to get pregnant. A woman who starts a GLP-1 receptor agonist for weight or metabolic reasons may find that her fertility improves more quickly than expected. Women with PCOS who have relied on irregular cycles as a form of natural contraception should not assume that pattern will continue once weight is lost and insulin resistance decreases. Discussing reliable contraception with a provider when starting a GLP-1 medication is appropriate for any woman not actively planning pregnancy.
On the other side of that equation, GLP-1 receptor agonists are not appropriate to use during pregnancy itself. Animal studies have shown fetal harm at exposures above clinical doses, and adequate human safety data during pregnancy are not available. The FDA prescribing information for semaglutide (Wegovy) states in its section on females of reproductive potential that patients should discontinue Wegovy at least two months before a planned pregnancy, because of the long half-life of semaglutide. Tirzepatide (Zepbound) carries similar guidance in its label.
This two-month washout window means family planning must be part of the initial GLP-1 conversation for any woman with PCOS who may want to conceive within the next year or two. A provider can help build a transition plan in advance, which might involve switching to metformin or relying on lifestyle-based approaches during the pre-conception and pregnancy period.
What the 2023 International PCOS Guideline recommends
The most current global consensus on PCOS management comes from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, published in The Journal of Clinical Endocrinology and Metabolism. On the topic of weight management, the guideline states that anti-obesity medications including GLP-1 receptor agonists such as liraglutide and semaglutide could be considered in addition to lifestyle intervention for adults with PCOS and higher weight.
The guideline is careful to note that no anti-obesity medication is approved specifically for PCOS. A systematic review conducted to inform the guideline, published in Obesity Reviews in 2024, found that while liraglutide and semaglutide appeared superior to placebo for weight-related outcomes in PCOS, the available data were too limited to draw firm conclusions on hormonal and reproductive endpoints. The authors described the published evidence base as "very limited" and called for larger, longer trials with standardized outcome measures.
Several phase 3 trials evaluating semaglutide in PCOS populations are currently recruiting or in progress. Until results from those trials are available, clinical guidance rests on smaller trials, mechanistic plausibility, and extrapolation from the broader obesity literature. This is an active research area where the evidence picture is expected to sharpen considerably over the next few years.
How GLP-1 receptor agonists compare to other common PCOS treatment approaches
Women with PCOS have several treatment pathways depending on their primary concerns. The table below offers a general orientation across common options. Note that these treatments have not been compared head-to-head against GLP-1 receptor agonists in large PCOS-specific trials, so this comparison is descriptive only, drawn from separate bodies of evidence in different study populations.
| Treatment | Primary mechanism | Menstrual cycle effects | Weight effects | FDA-approved for PCOS? |
|---|---|---|---|---|
| Combined oral contraceptives | Androgen suppression, cycle regulation | Regulates cycle directly | Neutral to modest gain | No (off-label) |
| Metformin | Insulin sensitization | Modest improvement over time | Modest reduction | No (off-label) |
| GLP-1 receptor agonists | Insulin resistance, appetite, weight | Improved in trials; primarily weight-mediated | Meaningful reduction | No (off-label for PCOS) |
| Spironolactone | Androgen blockade | May regulate cycle | Neutral | No (off-label) |
| Lifestyle modification | Weight, insulin sensitivity | Improved with 5 to 10 percent weight loss | Variable; foundational | N/A |
None of these treatments is FDA-approved specifically for PCOS. Most are prescribed off-label based on accumulated evidence and clinical guidelines. A clinician with experience in both PCOS and metabolic health is best positioned to discuss which combination makes sense for a particular patient's goals and medical history. For a detailed comparison of the two most widely prescribed options, see semaglutide vs tirzepatide.
Questions to bring to a provider before starting a GLP-1 for PCOS
The decision to use a GLP-1 receptor agonist in the context of PCOS benefits from a thorough clinical conversation. The topics below cover the most relevant ground. Not every woman with PCOS will be a candidate, and a clinician's assessment of individual health history, current medications, and goals is the essential starting point.
- Does my BMI or metabolic profile meet eligibility criteria for an FDA-approved GLP-1 medication? Current approvals for weight management require a BMI of 30 or higher, or 27 or higher with a weight-related condition. A provider can evaluate whether an approved medication or an off-label approach is most appropriate for a specific case.
- What does my insulin resistance look like on labs? A fasting insulin level, HOMA-IR calculation, and hemoglobin A1c can help clarify whether insulin resistance is a significant driver of current symptoms and how aggressive treatment should be.
- What are my family planning goals over the next one to two years? Because GLP-1 medications require stopping at least two months before a planned pregnancy, this discussion should happen before the prescription is written, not after.
- Am I currently on metformin or oral contraceptives? GLP-1s have been studied alongside metformin in PCOS with promising results, but any combination requires provider oversight. GLP-1s slow gastric emptying, which can temporarily affect the absorption of oral contraceptives, so method of contraception is worth reviewing.
- What monitoring is planned? Periodic weight checks, metabolic panels, and hormonal labs can help confirm whether improvements in insulin resistance and androgen levels are occurring over time.
- If a compounded product is being considered, what pharmacy is dispensing it? Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated in PCOS-specific trials. Knowing whether a pharmacy is a state-licensed 503A facility or an FDA-registered 503B outsourcing facility is part of understanding the regulatory context of what is being prescribed.